Study to Evaluate the Effect of Short Treatment With Nutritional Supplementation Standardized Innovative Formula, on Growth and Weight Gain in Short and Lean Prepubertal Children
NCT01158352 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200
Last updated 2014-11-07
Summary
Study design:
Double blind, randomized, placebo controlled study.The proposed study will consist of two main segments:
1. Segment 1 is aimed to assess the effect of 6-12 months treatment with nutritional supplementation standardized formula, in short and lean prepubertal children on weight SDS, height SDS, BMI SDS and growth velocity
2. Segment 2 is aimed to explore the eating behavior of idiopathic short stature and lean prepubertal children against their sibling who have a normal height and body weight and to find out whether there is a difference in eating patterns and quality of life between idiopathic short stature and lean prepubertal children and children with normal height and body weight
Segment 1
Population:
200 subjects and controls will be recruited to segment 1 of the proposed study, 100 at each group.
Participants will be recruited from healthy children who will be referred to either the institute for endocrinology or the gastroenterology unit, at Schneider Children's Medical Center for growth assessment, due to low height and weight, in whom, no gastrointestinal morbidity or other underlying cause was found.
Methods:
Randomization \& Blinding:
Participants will be randomly assigned either to the intervention group or the placebo control group. Randomization for the two study groups will be made in a ratio of 1:1. Both participants and study team will be blinded to the type of treatment that each patient will receive during the first 6 months of the study.
Treatment:
Participants in the intervention group will be treated with a nutritional supplementation standardized formula.Participants in the control group will be instructed to consume the same volume of formula as was calculated if they were in the intervention group.
Treatment duration:
The study will be divided into two treatment periods: 6 months of intervention versus active placebo followed with additional 6 months (an extension period), in which participants at the intervention group will be offered to extend the intervention period and participants at the control arm will be offered to switch to the intervention group.
Study Schedule:
Follow up visits will take place at 0, 3, 6, 9 and 12 months and will include:
1. Demographic data, medical history and growth data (month 0):
Demographic parameters, including birth date, gender, birth weight and length for gestational age, medical history and growth data, including height velocity, parent's and sibling's weight and height will be documented from patient's file.
2. Nutritional assessment
3. Anthropometric assessment (months 0, 3, 6, 9 12):
1. Height without shoes
2. Length
3. Weight with light cloths and without shoes
4. MAC
5. Body mass index (BMI) will be calculated from children's weight and height and age and gender specific BMI SDS will be calculated
6. Body composition assessment using the method of bioelectrical impedance
4. Laboratory parameters (months 0, 6 and 12):
5. Sleeping Questionaire
Segment 2:
86 subjects and controls will be recruited to segment 2 of the proposed study
Population:
Short and lean prepubertal children participating at segment 1 of the study and who are at study entry under 10th percentile in height, when the weight percentile is equal or smaller to the height percentile. Only participants from segment 1 who have siblings with normal height and body weight for age and gender, will be able to participate in segment 2 of the study
Control group 1:
Sibling of participants in segment 1 of the study, who have a normal height- above 25th percentile and normal BMI for age and gender- above 5th percentile and under 85th percentile.
Control group 2:
Healthy children from the community who have a normal height above 25th percentile and normal BMI for age and gender above 5th percentile and under 85th percentile
Segment 2 of the study will be designed as a case- control study and will focus on the eating patterns, sleeping patterns and quality of life of participants at segment 1 at time 0 month of the study, before the beginning of the nutrition intervention. These findings will be compared to data of a control group, which will be comprised of siblings of participants in segment 1, with normal height and body weight which are matched in age.
Conditions
- Growth
- Low Weight
- Low Height
Interventions
- DIETARY_SUPPLEMENT
-
Nutritional supplementation formula
Nutritional supplementation formula
- DIETARY_SUPPLEMENT
-
Placebo Comparator
Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals
Sponsors & Collaborators
-
Rabin Medical Center
lead OTHER
Principal Investigators
-
Moshe Phillip, Prof · Schenider Children's Medical
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 3 Years
- Max Age
- 8 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-11-30
- Primary Completion
- 2014-11-30
- Completion
- 2014-11-30
Countries
- Israel
More Related Trials
-
Nutritional Stimulation of Growth in Children With Short Stature
NCT04226586 ·Status: COMPLETED ·Phase: NA
-
Effects of Growth Hormone (GH) Treatment on Eating Regulation
NCT00562705 ·Status: COMPLETED ·Phase: NA
-
Biochemical Markers of Growth Response to Growth Hormone Treatment in Children With Idiopathic Short Stature
NCT00458263 ·Status: COMPLETED ·Phase: PHASE4
-
Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature
NCT00396097 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment Of Short Stature With Genotropin In Children Born Small For Gestational Age Until Final Height
NCT00174421 ·Status: COMPLETED ·Phase: PHASE3
-
Growth Retardation In Children With Special Pathological Conditions Or Disease
NCT00163215 ·Status: COMPLETED ·Phase: PHASE3
-
Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in Children
NCT03290235 ·Status: UNKNOWN ·Phase: PHASE4
-
Role of Nutrition and Hormones in Boys With Disordered Growth
NCT00102258 ·Status: COMPLETED ·Phase: PHASE2
-
A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height
NCT00840944 ·Status: UNKNOWN ·Phase: PHASE4
-
Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With Somatropin
NCT00488124 ·Status: COMPLETED ·Phase: PHASE2
-
Randomized Clinical Trial of Two Different Initial Growth Hormone Doses in Children
NCT06103513 ·Status: RECRUITING ·Phase: PHASE3
-
Efficacy and Safety of a High Dosage Compared to the Label Dosage of Somatropin in Early Pubertal Stage Children With Growth Hormone Deficiency
NCT00191165 ·Status: COMPLETED ·Phase: PHASE3
-
Nutrients and Hormones: Effects in Boys With Disordered Growth
NCT00139451 ·Status: COMPLETED ·Phase: PHASE2
-
Genotropin Treatment in Short Prepubertal Children With Intra-Uterine Growth Retardation
NCT01073605 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Growth Hormone in Children With Growth Hormone Deficiency
NCT00262249 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients
NCT01562834 ·Status: COMPLETED ·Phase: PHASE4
-
Free Fatty Acids, Body Weight, and Growth Hormones Secretion in Children
NCT01237041 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Individualizing Dose of Growth Hormone to Maintain Normal Growth Velocity After Fulfilled Catch up Growth in Children
NCT02879747 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess
NCT03882034 ·Status: COMPLETED ·Phase: PHASE3
-
A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature
NCT03255694 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia
NCT05353192 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty
NCT05341115 ·Status: COMPLETED ·Phase: PHASE4
-
A Study (Phase 1b/2) of GS3-007a Oral Treatment in Children With Growth Hormone Deficiency (PGHD)
NCT07264595 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency
NCT03249480 ·Status: UNKNOWN ·Phase: PHASE4
-
Predictive Value of the Insulin-like Growth Factor-1 (IGF-1) Generation Test for the Growth Response to Growth Hormone Treatment (PRED-IGF)
NCT01438801 ·Status: WITHDRAWN ·Phase: PHASE4